Seller record · Telehealth service

PlushCare

By Peptide Alliance, Editorial publisherRecorded September 2026 · Standard v1.1 · How checks are performed

Fails 2 of 8 criteria. S3, pharmacy identification: Each mention refers to the pharmacy of the patient's choice or an unnamed compounding partner. The terms, privacy, health-privacy notice, contact and treatment surfaces add no facility. 1 more criterion also fails; see the table below.

At a glance

PlushCareTelehealth service

6/8criteria passed

Price: Printed on its own pages before sign-up
Sells: brand GLP-1 prescriptions, compounded semaglutide, and 2 more
FDA letters: None on file

Visit PlushCare See all eight dispositions

Telehealth service. Passes 6 of 8 criteria. Recorded against Standard v1.1.

A primary-care telehealth service that prescribes brand and compounded GLP-1 drugs among many other treatments. It routes prescriptions to a pharmacy the patient chooses rather than to one it names.

Operating entity PlushCare of California, Inc., P.C.

Dispositions

Code	Criterion	Disposition	Where it appears
S1	Prescriber requirement	PASS	PlushCare's about page
S2	Prescription gating	PASS	PlushCare's onboarding page on its patient site
S3	Pharmacy identification	FAIL	PlushCare's Wegovy semaglutide prescription page
S4	Compounding disclosure	PASS	PlushCare's Wegovy semaglutide prescription page
S5	Analytical documentation	FAIL	PlushCare's semaglutide prescription page
S6	Business address	PASS	PlushCare's HIPAA notice of privacy practices page
S7	Price disclosure	PASS	PlushCare's semaglutide prescription page
S8	Enforcement status	PASS	FDA warning-letter index

Evidence, criterion by criterion

The evidence behind each disposition in the table above, where it appears, and its date.

S1PASSThe about page states that physicians are board certified and selected from fifty United States medical institutions, and it names no individual prescriber.Source: PlushCare's about page.

S2PASSA weight-loss onboarding survey opens with medical questions, before any payment field.Source: PlushCare's onboarding page on its patient site.

S3FAILEach mention refers to the pharmacy of the patient's choice or an unnamed compounding partner. The terms, privacy, health-privacy notice, contact and treatment surfaces add no facility.Source: PlushCare's Wegovy semaglutide prescription page.

S4PASSThe Wegovy page states that compounded semaglutide, like all compounded drugs, is not Food and Drug Administration approved.Source: PlushCare's Wegovy semaglutide prescription page.

S5FAILNo certificate, lot number or purity figure appears on the site.Source: PlushCare's semaglutide prescription page.

S6PASSThe health-privacy notice prints a street address with a suite number on Market Street in San Francisco, California.Source: PlushCare's HIPAA notice of privacy practices page.

S7PASSThe semaglutide page prints 129 dollars for a visit without insurance, and the homepage repeats that figure as the appointment fee.Source: PlushCare's semaglutide prescription page.

S8PASSNo FDA warning letter names the entity, and no action has halted the business.Source: FDA warning-letter index.

Products shown on the seller's own pages at the recorded date: brand GLP-1 prescriptions, compounded semaglutide, primary-care prescriptions, mental health prescriptions.

Other sellers of the same products

Who sells semaglutide

Visit PlushCare

Dispositions recorded against Standard v1.1. Method and null semantics: how checks are performed. This record is not a review and contains no medical advice.